Supranuclear Palsy, Progressive
"Supranuclear Palsy, Progressive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)
| Descriptor ID |
D013494
|
| MeSH Number(s) |
C10.228.140.079.882 C10.228.662.700 C10.292.562.750.500 C10.574.945.500 C10.597.622.447.690 C11.590.472.500 C23.888.592.636.447.690
|
| Concept/Terms |
Supranuclear Palsy, Progressive- Supranuclear Palsy, Progressive
- Progressive Supranuclear Palsies
- Supranuclear Palsies, Progressive
- Palsy, Progressive Supranuclear
- Progressive Supranuclear Ophthalmoplegia
- Progressive Supranuclear Palsy
- Steele-Richardson-Olszewski Disease
- Steele Richardson Olszewski Disease
- Steele-Richardson-Olszewski Syndrome
- Steele Richardson Olszewski Syndrome
- Syndrome, Steele-Richardson-Olszewski
- Supranuclear Palsy, Progressive, 1
- Ophthalmoplegia, Progressive Supranuclear
- Supranuclear Ophthalmoplegia, Progressive
- Richardson's Syndrome
- Richardson Syndrome
- Syndrome, Richardson's
|
Below are MeSH descriptors whose meaning is more general than "Supranuclear Palsy, Progressive".
Below are MeSH descriptors whose meaning is more specific than "Supranuclear Palsy, Progressive".
This graph shows the total number of publications written about "Supranuclear Palsy, Progressive" by people in this website by year, and whether "Supranuclear Palsy, Progressive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2022 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Supranuclear Palsy, Progressive" by people in Profiles.
-
Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome. Mov Disord. 2023 02; 38(2):304-312.
-
Recommendations for Virtual Administration of the PSP Rating Scale. Mov Disord. 2022 09; 37(9):1960-1961.
-
A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Mov Disord. 2022 06; 37(6):1265-1271.
-
Disease course and treatment patterns in progressive supranuclear palsy: A real-world study. J Neurol Sci. 2021 Feb 15; 421:117293.
-
Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
-
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019 06; 18(6):549-558.
-
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2019 03; 60:138-145.
-
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281.
-
Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016 Nov 08; 87(19):2016-2025.
-
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.